| Outcome Measures: |
Primary: Major acute cardiovascular events, In this work, this composite includes patients suffering from non-fatal acute myocardial infarction (AMI) and non-fatal stroke, transient ischemic attack (TIA), all-cause death, and, heart failure events occurring during the study period (from inclusion in the study until the event or the end of the study period, whichever came first)., From inclusion in the study, starting from 01/01/2014, until the event or the end of the study, on 31/12/2019, whichever came first. | Secondary: Major acute cardiovascular events without heart failure, In this work, this composite includes patients suffering from non-fatal acute myocardial infarction (AMI) and non-fatal stroke, transient ischemic attack (TIA) and all-cause death occurring during the study period (from inclusion in the study until the event or the end of the study period, whichever came first)., From inclusion in the study, starting from 01/01/2014, until the event or the end of the study, on 31/12/2019, whichever came first.|AMI, Acute myocardial infarction events occurring during the study follow-up (from inclusion in the study until the event or the end of the study period, whichever came first., From inclusion in the study, starting from 01/01/2014, until the event or the end of the study, on 31/12/2019, whichever came first.|Stroke, Stroke events occurring during the study follow-up (from inclusion in the study until the event or the end of the study period, whichever came first., From inclusion in the study, starting from 01/01/2014, until the event or the end of the study, on 31/12/2019, whichever came first.|Heart Failure, Heart failure hospitalization occurring during the study follow-up (from inclusion in the study until the event or the end of the study period, whichever came first., Through study completion (from inclusion in the study until the event or the end of the study period, whichever came first)|all-cause death, Death from all causes occurring during the study follow-up (from inclusion in the study until the event or the end of the study period, whichever came first., From inclusion in the study, starting from 01/01/2014, until the event or the end of the study, on 31/12/2019, whichever came first.|Renal progression, Sustained 40% reduction in eGFR occurring during the study follow-up (from inclusion in the study until the event or the end of the study period, whichever came first., From inclusion in the study, starting from 01/01/2014, until the event or the end of the study, on 31/12/2019, whichever came first.|atrial fibrillation, Events of atrial fibrillation episodes occurring during the study follow-up (from inclusion in the study until the event or the end of the study period, whichever came first., From inclusion in the study, starting from 01/01/2014, until the event or the end of the study, on 31/12/2019, whichever came first.|Hypoglycemia, Severe hypoglycemia requiring hospitalization occurring during the study follow-up (from inclusion in the study until the event or the end of the study period, whichever came first., From inclusion in the study, starting from 01/01/2014, until the event or the end of the study, on 31/12/2019, whichever came first.|Persistence, Persistence on treatment was defined as the percentage of patients continuing treatment from the start of the study period or since the first prescription during the study period until evidence of discontinuation or the end of the study period., From inclusion in the study, starting from 01/01/2014, until the end of the study, on 31/12/2019.|Adherence, Treatment adherence was defined as the proportion of days covered (days in which an individual had access to the medication) from the start of the study period or since the first prescription during the study period until treatment discontinuation, From inclusion in the study, starting from 01/01/2014, until the end of the study, on 31/12/2019.|Therapeutic inertia, Therapeutic inertia was defined as non-intensification of treatment once started despite HbA1c ≥7.5% during follow-up., From inclusion in the study, starting from 01/01/2014, until the end of the study, on 31/12/2019.
|
